Cardiology

Lp(a) is a genetically-driven and independent risk factor for CVD with no approved treatments. Lilly is advancing muvalaplin and has some good competition.

AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.

Aprocitentan is the first-and-only dual endothelin receptor antagonist approved for the treatment of systemic hypertension.

AHA 2024. "...we did not anticipate this magnitude of increase in mortality," researchers said. They were also surprised by the population groups most affected.

ObesityWeek 2024. Semaglutide 2.4 mg reduces rates of composite CV outcomes in high-risk patients without diabetes and now is shown to reduce inpatient care and length of stay.

Your daily dose of the clinical news you may have missed.

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.

Women remain underrepresented in heart disease research after decades of efforts to correct the balance, affecting trial data and women's cardiovascular care.

Prior SARS-CoV-2 infection was associated with a 2-fold increased risk for MACE for up to 3 years, even among people with no history of CVD, in a new analysis of UK Biobank data.

Your daily dose of the clinical news you may have missed.